Ashwagandha and Sleep: What the Trials Show

Ashwagandha (Withania somnifera) is unusual in the botanical sleep category for having actual randomised controlled trials behind it rather than tradition and testimonial. It is also frequently oversold, so here is what the evidence supports and where it stops.

What the trials found

Multiple randomised, placebo-controlled trials have examined ashwagandha extract for sleep quality and for stress, and meta-analyses of them point the same way: modest but real improvements in subjective sleep quality, sleep onset latency and perceived stress, with cortisol reductions reported in several.

Two things are worth noticing about that result.

The effects are modest. This is not a hypnotic. People do not take ashwagandha and fall unconscious. The change is in how easily sleep arrives and how restorative it feels, and it accumulates over weeks rather than appearing on night one.

The strongest responses are in stressed populations. The trials that show the clearest benefit are generally in people with elevated stress or anxiety. That fits the proposed mechanism — ashwagandha is classed as an adaptogen, and the sleep benefit appears to be largely downstream of the stress effect rather than a direct sedative action.

Which tells you who it suits: people whose sleep problem is a mind that will not settle. It tells you equally clearly who it does not suit — people whose sleep problem is an airway.

Dose and standardisation

The doses used in the trials generally sit in the 300–600mg per day range of a standardised root or leaf extract, most commonly taken as 300mg once or twice daily.

Standardisation is the number that matters and most labels bury it. Extracts are standardised to withanolides, the active constituents, typically at 2.5% to 5%. An extract at 5% withanolides delivers roughly twice the actives of one at 2.5% at the same milligram figure, so "300mg of ashwagandha" without a standardisation percentage is not a meaningful claim.

For reference, AGZ states 300mg of ashwagandha leaf extract standardised to 5% withanolides — a research-range dose with the standardisation disclosed, which is more than most products manage. Seed PM-02 names ashwagandha alongside low-dose melatonin without publishing the dose on its listing.

Effects build over four to twelve weeks. A one-week trial tells you nothing.

Root, leaf and branded extracts

Traditional use is of the root. Many modern extracts are root-based; some, including several premium formulas, use leaf extract or a combination. The clinical literature is dominated by root extracts, with branded standardised versions appearing most often in trials — which is a reason to prefer products that name what they use.

The cautions

Ashwagandha is generally well tolerated, and the common side effects are mild gastrointestinal upset and drowsiness. Several cautions are worth stating plainly.

None of that makes it a dangerous product. It makes it a product with real pharmacological activity, which is the same reason it works.

What it does for snoring

Nothing. It does not widen an airway, reduce nasal resistance or change palatal tone.

The relevant question for this audience is whether it makes snoring worse — and the answer appears to be no. It is classed as adaptogenic rather than sedating, and it does not carry the airway-tone concern that applies to antihistamines, benzodiazepines and alcohol. The list of things that do.

That makes it one of the safer actives for a snorer to include, if you want something for the stress side of a sleep problem. It is still a last layer, after the airway work. The stack in order.